openalexFrontiers in Oncology2026-07-24
Case Report: Long-term survival in extensive-stage small cell lung cancer treated with adebrelimab-based combination therapy
Xia Y, Yuxian Yang, Wanzhong Huang, Yongshun Chen
The integration of immune checkpoint inhibitors into first-line treatment has markedly improved outcomes for extensive-stage small cell lung cancer (ES-SCLC). Adebrelimab, a PD-L1 inhibitor, demonstrated superior overall survival in the phase 3 CAPSTONE-1 trial. We present a deta…